ENDPOINTS

Can amylin drugs take over from GLP-1s in obesity? Partnerless Zealand thinks so

Zealand Pharma investors eager for news of a partnering deal for the Danish group’s mid-stage asset petrelintide had a disappointing Thursday morning as the company’s 2024 results came without a big ...

Feb 20, 2025 - 12:33
 0
Can amylin drugs take over from GLP-1s in obesity? Partnerless Zealand thinks so
Zealand Pharma investors eager for news of a partnering deal for the Danish group’s mid-stage asset petrelintide had a disappointing Thursday morning as the company’s 2024 results came without a big ...
Read More

Tags:

Previous Article

Rare genetic disorder treated in womb for the first time

Next Article

EG 427 collects €27M in Series B to advance overactive bladder treatment

Related Posts

Achira raises $33M Nvidia-backed seed round, blending AI and physics in biotech

Achira raises $33M Nvidia-backed seed round, blending A...

Feb 21, 2025  0

David Baker lab makes de novo enzymes with AI

David Baker lab makes de novo enzymes with AI

Feb 13, 2025  0

Summer buys Caraway, as startups keep deals in the VC family

Summer buys Caraway, as startups keep deals in the VC f...

Feb 11, 2025  0